Contact Us
admin@ausbiotech.org
Member Login
Search
Member Login
Home
About AusBiotech
About us
Team
Board
Committees
Contact us
Biotechnology Industry
Overview
Directories
Careers
Events
Conferences
Event calendar
State events
Investment events
International events
Partnership opportunities
BiotechTalks Library - member benefit
Sector events
Member Services
Member benefits
Become a member
Student membership
Business Solutions Programme
Investing in Biotech
Investment events
For life sciences companies
For life sciences investors
Industry highlights
ASX-listed biotechs
Programmes
AusBioNSW
AusMedtech
International engagement
Biotherapeutics
Clinical trials
Australia's Cell and Gene Catalyst
Regenerative Medicines Consortium Project
Biotech board enhancement
Global Investment Programme
Industry Growth Program - an AusIndustry initiative
Newsroom
Media Releases
THRIVE
AusBiotech Updates
Biotech Dispatch
AusBioNSW Updates
Publications
Photo galleries
Policy & Advocacy
2025-26 Pre-Budget Submission with MTPConnect
2025-26 Pre-Budget Submission with Medicines Australia
Development & Commercialisation Summit Outcomes & Communique
Development & Commercialisation Summit Discussion Paper
2025-26 Pre-Budget Submission Cell and Gene Catalyst
Biotechnology Blueprint
Home
Newsroom
Newsroom
.
US FDA IND approval for Dimerix late-stage study
10 May 2022
